Literature DB >> 3097811

Serum and plasma fibronectin binds to complement reacted immune complexes primarily via Clq.

G Baatrup, S E Svehag.   

Abstract

The binding of fibronectin to human Clq, C3b, and complement-reacted immune complexes (IC) was investigated by enzyme-linked immunosorbent assays. Microplates were coated with BSA followed by incubation with rabbit-anti-BSA IgG or F(ab')2 fragments of rabbit anti-BSA. Incubation of the solid phase with serum at 37 degrees C caused attachment of Clq and C3b. Addition of EDTA to the serum inhibited the binding of C3b, but not Clq, whereas substitution of the anti-BSA IgG on the solid phase with the F(ab')2 fragments abrogated the Clq, but not the C3b binding. Fibronectin binding was observed after incubation of the solid-phase IC with serum or plasma at conditions where Clq was also bound, whereas only minor amounts of fibronectin bound to the solid phase IC via C3b. Purified fibronectin showed a dose-dependent binding to solid-phase IC pretreated with Clq or fibronectin-depleted serum, confirming that the binding of fibronectin to IC largely occurred via Clq. Significantly smaller amounts of fibronectin were bound to solid-phase IC incubated with plasma instead of serum, despite the higher fibronectin concentration in plasma. This difference was found not to be due to a fibrinogen-fibronectin interaction in plasma. Binding of fibronectin to preformed fluid phase IC incubated with serum was demonstrated by SDS-PAGE analysis of PEG-precipitated IC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3097811     DOI: 10.1111/j.1365-3083.1986.tb02174.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

1.  The influence of anti-fibronectin antibodies on interactions involving extracellular matrix components and cells: a possible pathogenic mechanism.

Authors:  M S Atta; R J Powell; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

2.  Lack of binding between cryoimmunoglobulins, immunoglobulins and fibronectin: implications for immune complex vasculitis.

Authors:  D T Brandau; R O'Donnell; V L Kimmel-Truitt
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

3.  Human anti-fibronectin antibodies in systemic lupus erythematosus: occurrence and antigenic specificity.

Authors:  M S Atta; R J Powell; N D Hopkinson; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.